Medtronic (NYSE: MDT ) is expected to report Q4 earnings on May 21. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medtronic's revenues will increase 2.1% and EPS will grow 4.0%.
The average estimate for revenue is $4.39 billion. On the bottom line, the average EPS estimate is $1.03.
Last quarter, Medtronic logged revenue of $4.03 billion. GAAP reported sales were 2.8% higher than the prior-year quarter's $3.92 billion.
Last quarter, non-GAAP EPS came in at $0.93. GAAP EPS of $0.97 for Q3 were 10% higher than the prior-year quarter's $0.88 per share.
For the preceding quarter, gross margin was 75.2%, 100 basis points worse than the prior-year quarter. Operating margin was 28.2%, 70 basis points worse than the prior-year quarter. Net margin was 24.5%, 60 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $16.52 billion. The average EPS estimate is $3.69.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,711 members out of 1,804 rating the stock outperform, and 93 members rating it underperform. Among 496 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 481 give Medtronic a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medtronic is outperform, with an average price target of $46.71.
Is Medtronic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Medtronic to My Watchlist.